[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388022":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":26,"studyPopulation":26,"armGroups":33,"interventions":42,"overallOfficials":62,"centralContacts":66,"locations":74,"responsibleParty":92,"collaborators":26,"id":94,"slug":26,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":26,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":26,"enrollmentInfo":102,"targetDuration":26,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":26,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"To estimate overall response rate","Overall response rate (ORR) as determined by RECIST criteria. Response will be defined by a complete response (CR) or partial response (PRO), confirmed or unconfirmed.","3 years",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"Progression-free survival","Progression-free survival (PFS) defined as the duration from the first study dose of study drug until progressive disease, death or last assessment contact whichever comes first.","From first dose of study drug until progressive disease, death or last assessment contact, whichever comes first, an average of 1-2 years",{"measure":19,"description":20,"timeFrame":21},"Overall Survival","Overall Survival (OS) is defined as the time from the first dose of study drug until death due to any cause or last observation or contact.","from the first dose of study drug until death, last observation or contact, an average of 1-2 years",{"measure":23,"description":24,"timeFrame":25},"Safety Evaluations: number of Grade ≥ 3 as determined by CTCAE v 5.0","Toxicity will be estimated by the number of Grade ≥ 3 as determined by CTCAE v 5.0.","Initiation through 30 days following the last administration of study treatment.",null,{"allocation":28,"interventionModel":29,"interventionModelDescription":26,"primaryPurpose":30,"observationalModel":26,"timePerspective":26,"maskingInfo":31},"NA","SINGLE_GROUP","TREATMENT",{"masking":32,"maskingDescription":26,"whoMasked":26},"NONE",[34],{"label":35,"type":36,"description":37,"interventionNames":38},"Carboplatin, Taxane And Ramucirumab","EXPERIMENTAL","Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg\u002Fm2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg\u002Fkg IV every 3 weeks",[39,40,41],"Drug: Carboplatin","Drug: Paclitaxel","Drug: Ramucirumab",[43,50,56],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","Carboplatin","Carboplatin IV",[35],[49],"Paraplatin",{"type":44,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Paclitaxel","Paclitaxel IV",[35],[55],"Abraxane, Taxol",{"type":44,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Ramucirumab","Ramucirumab IV",[35],[61],"Cyramza",[63],{"name":64,"affiliation":5,"role":65},"Melina Marmarelis, MD","PRINCIPAL_INVESTIGATOR",[67,72],{"name":68,"role":69,"phone":70,"phoneExt":26,"email":71},"Melissa Volpe, BA","CONTACT","215-220-9703","Melissa.volpe@pennmedicine.upenn.edu",{"name":64,"role":69,"phone":73,"phoneExt":26,"email":26},"267-438-8154",[75],{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Abramson Cancer Center of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":84,"coordinates":85},"Point",[86,87],-75.16362,39.95238,{"lat":87,"lon":86},[90],{"name":91,"role":69,"phone":70,"phoneExt":26,"email":71},"Melissa Volpe",{"type":93,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100388022",false,"NCT04332367","Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And\u002FOr Pembrolizumab","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to 4-6 cycles of Pem\u002FCarbo\u002FPembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.\n* PS 0-1\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* Other active invasive malignancy requiring ongoing therapy\n* Grade 2 or higher sensory neuropathy\n* Evidence of untreated brain metastases\n* History of bleeding diatheses or recent, antecedent hemoptysis (\\> 1\u002F2 teaspoon in prior 2 months)","ALL","18 Years",{"count":103,"type":104},59,"ESTIMATED","INTERVENTIONAL",[107],"PHASE2","The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.",[110],"Non-small Cell Lung Cancer","2026-06-08",{"date":113,"type":114},"2026-06-10","ACTUAL",{"date":116,"type":114},"2020-08-01",{"date":118,"type":104},"2026-09-30",{"name":5,"class":6},1]